Trials / Completed
CompletedNCT02372630
The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- University at Buffalo · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center, prospective randomized double blind, parallel and placebo controlled study to evaluate oxidative stress and inflammation before and after treatment with linagliptin for 12 weeks. We will also, testing whether Linagliptin is an insulin sensitizer.
Detailed description
This is a single center, prospective randomized double blind, parallel and placebo-controlled study to evaluate oxidative stress and inflammation before and after treatment with linagliptin for 12 weeks. The study enrolls type 2 patients with diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Linagliptin | 5 mg daily oral tablets of linagliptin |
| DRUG | Placebo | matching placebo giving orally daily |
Timeline
- Start date
- 2014-05-23
- Primary completion
- 2018-02-01
- Completion
- 2018-05-01
- First posted
- 2015-02-26
- Last updated
- 2023-02-21
- Results posted
- 2023-02-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02372630. Inclusion in this directory is not an endorsement.